Zacks Investment Research upgraded shares of INTREXON CORP (XON) from UNDERPERFORM to NEUTRAL on October 22, 2014, with a target price of $19.20.
Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform Cell Systems Informatics LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on INTREXON CORP (XON),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment